The Globe and Mail reports in its Friday, Nov. 7, edition that TD Cowen analyst Mario Mendonca has reiterated his "buy" recommendation for Sun Life Financial. The Globe's David Leeder writes in the Eye On Equities column that Mr. Mendonca gave his share target a $2 trim to $99. Analysts on average target the shares at $93.54. Mr. Mendonca says in a note: "Sun Life Financial missed our estimate on weak U.S. results. While we did not expect a strong quarter, results reflect weaker experience in stop-loss and higher claims frequency in dental. In stop-loss, Sun Life also built reserves on the 1/1/25 cohort. The risk is that more claims data in Q4/25 could lead to further charges. Conservative reserving and pricing (on the 1/1/26 cohort) should drive better results in '26." The Globe reported on Nov. 6, 2024, that Mr. Mendonca had reaffirmed his "hold" recommendation for Sun Life Financial. The shares were going for $79.94. The Globe reported on Oct. 31, 2025, that CIBC World Markets analyst Paul Holden had lowered his ranking for Sun Life Financial to "neutral" from "outperformer." The shares could then be had for $85.48.